In a study analyzing 39 cases of SMARCB1-deficient sinonasal carcinoma, 22 patients were most frequently selected for surgery and chemoradiation, with a disease-free survival rate of 30% during the 11-115 months of follow-up. The gene discussed is SMARCB1; the disease is nasal cavity and paranasal sinus carcinoma.